メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
冨田 章裕
医学部・血液内科学
h-index
4361
被引用数
33
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1998 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(112)
類似のプロファイル
(6)
フィンガープリント
Akihiro Tomitaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Hematology
100%
Myelodysplastic Syndrome
79%
Pembrolizumab
75%
Classical Hodgkin Lymphoma
66%
Overall Survival
60%
T Cell
55%
Bleeding
54%
Waldenström's Macroglobulinemia
50%
Prognostic Factor
50%
Hemosiderin
50%
Human Leukocyte Antigen
50%
T Lymphocyte Receptor
50%
Asciminib
50%
Essential Thrombocythaemia
50%
Polycythemia vera
50%
Large-Cell Lymphoma
50%
Brentuximab Vedotin
48%
Diffuse Large B-Cell Lymphoma
46%
Neoplasm
43%
Retrospective Study
37%
Disease
36%
Iron Storage
35%
Programmed Cell Death
35%
Bosutinib
34%
Leukemia
33%
Monotherapy
33%
B Cell
30%
Central Nervous System
30%
Thrombosis
29%
Myeloid Leukemia
27%
Subgroup Analysis
27%
Decitabine
26%
Clinical Trial
26%
Iron Overload
26%
Deferasirox
26%
Autologous Stem Cell Transplantation
25%
Hepatitis B
25%
Hepatitis B Virus
25%
Leukemia Relapse
25%
Bortezomib
25%
Non-Hodgkin Lymphoma
25%
Ferritin
25%
B Lymphocyte Induced Maturation Protein 1
25%
B Lymphocyte Receptor
25%
Azacitidine
25%
Mantle Cell Lymphoma
25%
Circulating Tumor DNA
25%
Beta-Catenin
25%
PI3K/AKT Pathway
25%
Immunocompromised Patient
25%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
75%
Pembrolizumab
50%
Myelodysplastic Syndrome
50%
Neoplasm
50%
Nonhodgkin Lymphoma
50%
Rituximab
50%
Asciminib
50%
Thrombocythemia
50%
Classical Hodgkin Lymphoma
41%
Disease
39%
Brentuximab Vedotin
35%
Bosutinib
34%
Infection
34%
Bleeding
31%
Acute Myeloid Leukemia
30%
Decitabine
28%
Clinical Trial
26%
Chemotherapy
25%
Bortezomib
25%
Retrospective Study
25%
Hodgkin Disease
25%
Waldenstroem macroglobulinemia
25%
Azacitidine
25%
Mantle Cell Lymphoma
25%
Burkitt's Lymphoma
25%
Protein Tyrosine Kinase Inhibitor
25%
Emetine
25%
Core Binding Factor Beta
25%
Thrombotic Thrombocytopenic Purpura
25%
Mixed Connective Tissue Disease
25%
Circulating Tumor DNA
25%
Promyelocytic Leukemia
25%
Tumor Lysis Syndrome
25%
Syndrome
25%
Chronic Myeloid Leukemia
25%
Zinc Finger and BTB Domain Containing Protein 16
25%
Retinoic Acid Receptor
25%
Promyelocytic Leukemia Protein
25%
Ravulizumab
25%
Paroxysmal Nocturnal Hemoglobinuria
25%
Benzodiazepine
25%
Immunocompromised Patient
25%
Monotherapy
25%
Thyroid Hormone Receptor
25%
Biological Marker
25%
3 Hydroxykynurenine
25%
Kynurenic Acid
25%
Polycythemia vera
25%
Overall Survival
22%
Progression Free Survival
20%
Keyphrases
Hematology
75%
Pembrolizumab
50%
Predictive Significance
50%
Diffuse Large B-cell Lymphoma (DLBCL)
35%
CD20 Expression
32%
Combination Chemotherapy
32%
Rituximab Maintenance
28%
Thrombosis
28%
CD20-negative
27%
Flow Cytometric
25%
Mutation-negative
25%
Successful Treatment
25%
Waldenström Macroglobulinemia
25%
Refractory Hodgkin Lymphoma
25%
Primary Cutaneous
25%
Acute Myeloid Leukemia
25%
CD30+ Lymphoproliferative Disorders
25%
Bortezomib
25%
Classic Hodgkin Lymphoma
25%
Circulating Tumor DNA (ctDNA)
25%
B Lymphocyte-induced Maturation protein-1
25%
MYD88 L265P mutation
25%
Spinal Cord
25%
Molecular Targeted Therapy
25%
VR-CAP
25%
Mantle Cell Lymphoma
25%
Hematopoietic Function
25%
5-Aza-dC
25%
HDAC Complexes
25%
Beta-catenin
25%
Azacitidine
25%
Escape Mechanism
25%
Differentiation Syndrome
25%
Antibody Therapy
25%
COVID-19 mRNA Vaccination
25%
Allogeneic Hematopoietic Stem Cell Transplant Recipients
25%
Emetine
25%
MYC Rearrangement
25%
Relapsed or Refractory
25%
VPS13B
25%
Cohen Syndrome
25%
RUNX1-RUNX1T1
25%
Mixed Connective Tissue Disease
25%
Patient-derived
25%
KIT mutation
25%
CBFB-MYH11
25%
Primary Lymphoma
25%
Font
25%
Indolent Lymphoma
25%
High Tumor Burden
25%
